Want to see HK:1875 full AI Analyst Report?
TOT BIOPHARM International Co. Ltd. (1875) Ratios
TOT BIOPHARM International Co. Ltd. Ratios
HK:1875's free cash flow for Q2 2026 was $-53.71M. For the 2026 fiscal year, HK:1875's free cash flow was decreased by $-6.28M and operating cash flow was $-47.43M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.05 | 1.79 | 1.81 | 2.46 | 1.17 |
| Quick Ratio | 1.66 | 1.53 | 1.47 | 2.11 | 1.02 |
| Cash Ratio | 1.20 | 0.92 | 0.92 | 1.52 | 0.59 |
| Solvency Ratio | -0.03 | 0.09 | 0.01 | -0.02 | -0.60 |
| Operating Cash Flow Ratio | 0.06 | 0.28 | 0.15 | 0.22 | -0.67 |
| Short-Term Operating Cash Flow Coverage | 0.30 | 1.67 | 1.36 | 0.79 | -1.20 |
| Net Current Asset Value | $ -72.59M | $ -35.84M | $ -46.24M | $ 130.21M | $ -69.21M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.30 | 0.26 | 0.24 | 0.23 | 0.29 |
| Debt-to-Equity Ratio | 0.61 | 0.54 | 0.50 | 0.41 | 0.62 |
| Debt-to-Capital Ratio | 0.38 | 0.35 | 0.33 | 0.29 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.35 | 0.31 | 0.31 | 0.23 | 0.15 |
| Financial Leverage Ratio | 2.01 | 2.07 | 2.08 | 1.77 | 2.12 |
| Debt Service Coverage Ratio | -0.02 | 1.07 | 0.22 | -0.07 | -1.51 |
| Interest Coverage Ratio | -7.61 | 4.18 | -6.39 | -5.92 | -105.23 |
| Debt to Market Cap | 0.24 | 0.32 | 0.27 | 0.21 | 0.10 |
| Interest Debt Per Share | 0.55 | 0.56 | 0.48 | 0.46 | 0.37 |
| Net Debt to EBITDA | -42.86 | 0.17 | -0.57 | 23.73 | -0.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.03% | 71.24% | 73.53% | 83.82% | 36.00% |
| EBIT Margin | -10.77% | 4.20% | -4.17% | -9.83% | -339.01% |
| EBITDA Margin | -0.17% | 7.74% | 1.34% | -1.22% | -294.15% |
| Operating Profit Margin | -12.13% | 3.76% | -4.24% | -8.84% | -340.26% |
| Pretax Profit Margin | -13.42% | 3.16% | -4.84% | -11.32% | -342.24% |
| Net Profit Margin | -13.42% | 3.16% | -4.84% | -11.29% | -342.24% |
| Continuous Operations Profit Margin | -13.42% | 3.16% | -4.84% | -11.32% | -342.24% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 99.74% | 100.00% |
| EBT Per EBIT | 110.67% | 84.25% | 114.20% | 128.07% | 100.58% |
| Return on Assets (ROA) | -7.97% | 2.30% | -2.65% | -3.96% | -36.78% |
| Return on Equity (ROE) | -16.03% | 4.76% | -5.50% | -6.99% | -77.95% |
| Return on Capital Employed (ROCE) | -9.20% | 3.77% | -3.17% | -3.96% | -57.78% |
| Return on Invested Capital (ROIC) | -8.71% | 3.54% | -3.04% | -3.67% | -43.49% |
| Return on Tangible Assets | -8.11% | 2.31% | -2.66% | -3.97% | -37.76% |
| Earnings Yield | -6.16% | 2.85% | -2.92% | -3.68% | -13.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.46 | 5.70 | 5.55 | 7.06 | 3.22 |
| Payables Turnover | 7.71 | 7.29 | 5.79 | 2.75 | 1.73 |
| Inventory Turnover | 3.39 | 2.91 | 1.57 | 0.75 | 1.20 |
| Fixed Asset Turnover | 1.10 | 1.49 | 1.10 | 0.79 | 0.21 |
| Asset Turnover | 0.59 | 0.73 | 0.55 | 0.35 | 0.11 |
| Working Capital Turnover Ratio | 2.43 | 3.44 | 2.19 | 1.98 | 0.63 |
| Cash Conversion Cycle | 109.30 | 139.57 | 235.73 | 402.83 | 207.68 |
| Days of Sales Outstanding | 48.95 | 64.06 | 65.79 | 51.73 | 113.28 |
| Days of Inventory Outstanding | 107.70 | 125.55 | 233.01 | 483.63 | 305.21 |
| Days of Payables Outstanding | 47.35 | 50.04 | 63.08 | 132.52 | 210.81 |
| Operating Cycle | 156.65 | 189.61 | 298.80 | 535.35 | 418.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.02 | 0.16 | 0.08 | 0.09 | -0.31 |
| Free Cash Flow Per Share | -0.04 | -0.01 | -0.20 | -0.28 | -0.51 |
| Dividend Paid and CapEx Coverage Ratio | 0.37 | 0.94 | 0.28 | 0.25 | -1.52 |
| Capital Expenditure Coverage Ratio | 0.37 | 0.94 | 0.28 | 0.25 | -1.52 |
| Operating Cash Flow Coverage Ratio | 0.04 | 0.29 | 0.16 | 0.21 | -0.84 |
| Operating Cash Flow to Sales Ratio | 0.02 | 0.11 | 0.07 | 0.14 | -2.29 |
| Free Cash Flow Yield | -1.65% | -0.59% | -11.34% | -13.30% | -14.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.04 | 35.08 | -34.29 | -27.14 | -7.63 |
| Price-to-Sales (P/S) Ratio | 2.18 | 1.11 | 1.66 | 3.06 | 26.12 |
| Price-to-Book (P/B) Ratio | 2.60 | 1.67 | 1.89 | 1.90 | 5.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -60.47 | -170.02 | -8.82 | -7.52 | -6.86 |
| Price-to-Operating Cash Flow Ratio | 100.88 | 10.47 | 22.94 | 22.61 | -11.38 |
| Price-to-Earnings Growth (PEG) Ratio | 0.04 | -0.18 | 1.03 | 0.33 | 0.78 |
| Enterprise Value Multiple | -1306.19 | 14.52 | 123.34 | -226.93 | -9.13 |
| Enterprise Value | 1.68B | 1.23B | 1.29B | 1.23B | 2.05B |
| EV to EBITDA | -1306.19 | 14.52 | 123.34 | -226.93 | -9.13 |
| EV to Sales | 2.25 | 1.12 | 1.65 | 2.77 | 26.85 |
| EV to Free Cash Flow | -62.52 | -172.00 | -8.78 | -6.81 | -7.06 |
| EV to Operating Cash Flow | 104.30 | 10.60 | 22.83 | 20.47 | -11.70 |
| Tangible Book Value Per Share | 0.83 | 1.00 | 0.93 | 1.11 | 0.55 |
| Shareholders’ Equity Per Share | 0.86 | 1.01 | 0.95 | 1.12 | 0.58 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.03 | 1.51 | 1.08 | 0.69 | 0.13 |
| Net Income Per Share | -0.14 | 0.05 | -0.05 | -0.08 | -0.46 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.25 | 0.75 | 1.16 | 1.15 | 1.01 |
| Research & Development to Revenue | 0.11 | 0.07 | 0.13 | 0.34 | 2.81 |
| SG&A to Revenue | 0.54 | 0.63 | 0.09 | 0.14 | 0.74 |
| Stock-Based Compensation to Revenue | -0.00 | 0.01 | 0.01 | 0.04 | 0.07 |
| Income Quality | -0.16 | 3.35 | -1.49 | -1.20 | 0.67 |
Currency in CNY